A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/506 (2006.01) A61K 31/4545 (2006.01) A61K 31/496 (2006.01) A61K 31/501 (2006.01) A61K 31/5377 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01)
Patent
CA 2634235
The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists, sibutramine, phentermine and topiramate; and option one or more HMG- CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
La présente invention concerne des compositions pharmaceutiques comprenant les combinaisons thérapeutiques suivantes : un ou plusieurs antagonistes/agonistes inverses de H3 ; un ou plusieurs modérateurs de l'appétit choisis dans le groupe comprenant des antagonistes/agonistes inverses de CBi, la sibutramine, la phentermine et le topiramate ; et facultativement un ou plusieurs inhibiteurs de la HMG-CoA réductase. L'invention concerne également des médicaments et des kits comprenant les compositions pharmaceutiques de la présente invention et des procédés de traitement de l'obésité, des troubles liés à l'obésité et du diabète à l'aide des compositions pharmaceutiques de la présente invention.
Aslanian Robert G.
Berlin Michael Y.
Graziano Michael P.
Hwa Joyce J.
Kowalski Timothy J.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
LandOfFree
Combination of an h3 antagonist/inverse agonist and an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of an h3 antagonist/inverse agonist and an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of an h3 antagonist/inverse agonist and an... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1373667